Categories: Technology

FTC Solar to Announce Third Quarter Financial Results Tuesday, November 12, 2024

AUSTIN, Texas, Nov. 05, 2024 (GLOBE NEWSWIRE) — FTC Solar, Inc. (Nasdaq: FTCI), a leading provider of solar tracker systems, software, and engineering services, today announced it will report its third quarter financial results before market open on Tuesday, November 12, 2024.

A conference call for members of the investment community will be held at 8:30 a.m. E.T. that same day, during which the Company will discuss its third quarter 2024 results, its outlook and other business items. This call will be webcast and can be accessed within the Investor Relations section of the FTC Solar corporate website at investor.ftcsolar.com. A replay of the conference call will also be available on the website for 30 days following the webcast.

About FTC Solar, Inc.
Founded in 2017 by a group of renewable energy industry veterans, FTC Solar is a leading provider of solar tracker systems, technology, software, and engineering services. Solar trackers significantly increase energy production at solar power installations by dynamically optimizing solar panel orientation to the sun. FTC Solar’s innovative tracker designs provide compelling performance and reliability, with an industry-leading installation cost-per-watt advantage.

FTC Solar Investor Contact:
Bill Michalek
Vice President, Investor Relations
FTC Solar
T: (737) 241-8618
E: IR@FTCSolar.com

GlobeNews Wire

Recent Posts

KFSHRC Madinahs Virtual Clinics Wins Award at PX Congress

RIYADH, Saudi Arabia, Nov. 20, 2024 (GLOBE NEWSWIRE) -- King Faisal Specialist Hospital and Research…

5 hours ago

IBA Business Update Third Quarter 2024

Louvain-la-Neuve, Belgium, 21 November 2024 - IBA (Ion Beam Applications S.A), the world leader in…

5 hours ago

Novartis upgrades mid-term guidance and highlights deep pipeline in core therapeutic areas to drive long-term growth

Ad hoc announcement pursuant to Art. 53 LR Mid-term sales guidance upgraded to +6% CAGR…

5 hours ago

Kura Oncology and Kyowa Kirin Announce Global Strategic Collaboration to Develop and Commercialize Ziftomenib in Acute Leukemias

– Kura to receive a $330 million upfront payment and up to $1.2 billion in…

5 hours ago

Onco360 Has Been Selected as a National Specialty Pharmacy Partner for Revuforj (revumenib)

LOUISVILLE, Ky., Nov. 20, 2024 (GLOBE NEWSWIRE) -- Onco360®, the nation’s leading independent Specialty Pharmacy,…

5 hours ago

Las Vegas Unveils Exclusive Entertainment, Packages and More for Race Week 2024

Destination Revving up This Year’s Excitement with Top-Tier Entertainment, Luxurious Trackside Experiences and Celebrations like…

8 hours ago